Cargando…

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis

Glioblastoma (GBM) is the most common high-grade primary brain tumor in adults. Standard multi-modality treatment of glioblastoma with surgery, temozolomide chemotherapy, and radiation results in transient tumor control but inevitably gives way to disease progression. The need for additional therape...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaka, Nagham, Hafazalla, Karim, Samawi, Haider, Simpkin, Andrew, Perry, James, Sahgal, Arjun, Das, Sunit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895972/ https://www.ncbi.nlm.nih.gov/pubmed/31689995 http://dx.doi.org/10.3390/cancers11111723

Ejemplares similares

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review
por: Hafazalla, Karim, et al.
Publicado: (2018)

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
por: Weller, Johannes, et al.
Publicado: (2023)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

Editorial: Contemporary Management of Intracranial Metastatic Disease
por: Das, Sunit, et al.
Publicado: (2019)

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2015)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

Diffusion MRI Characteristics After Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma
por: Chang, Warren, et al.
Publicado: (2015)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

MOLECULAR PROFILING TO UNDERSTAND TREATMENT RESISTANCE AND RESPONSE IN GLIOBLASTOMA
por: Nikolopoulos, Marina, et al.
Publicado: (2023)

Newly diagnosed glioblastoma: adverse socioeconomic factors correlate with delay in radiotherapy initiation and worse overall survival
por: Pollom, Erqi L, et al.
Publicado: (2018)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome
por: Weller, Michael, et al.
Publicado: (2016)

Newly diagnosed glioblastoma in geriatric (65 +) patients: impact of patients frailty, comorbidity burden and obesity on overall survival
por: Schneider, Matthias, et al.
Publicado: (2020)

Feasibility, Safety and Impact on Overall Survival of Awake Resection for Newly Diagnosed Supratentorial IDH-Wildtype Glioblastomas in Adults
por: Moiraghi, Alessandro, et al.
Publicado: (2021)

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients
por: Guzauskas, Gregory F, et al.
Publicado: (2018)

Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases
por: Soliman, Hany, et al.
Publicado: (2016)

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
por: Wen, Qiuting, et al.
Publicado: (2014)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

Perioperative red blood cell transfusion is associated with poor functional outcome and overall survival in patients with newly diagnosed glioblastoma
por: Schneider, Matthias, et al.
Publicado: (2021)

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
por: Carter, Tonia C., et al.
Publicado: (2018)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
por: Gleeson, Jack Patrick, et al.
Publicado: (2019)

Correction: Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Interstitial photodynamic therapy for newly diagnosed glioblastoma
por: Quach, Stefanie, et al.
Publicado: (2023)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

BEVACIZUMAB FOR SYMPTOMATIC RADIATION NECROSIS IN BRAIN METASTASES: OUTCOMES FROM A SINGLE-CENTER RETROSPECTIVE ANALYSIS
por: Roberto, Katrina, et al.
Publicado: (2023)

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials
por: Du, Chigang, et al.
Publicado: (2016)

Impact of Neoadjuvant Bevacizumab on Neuroradiographic Response and Histological Findings Related to Tumor Stemness and the Hypoxic Tumor Microenvironment in Glioblastoma: Paired Comparison Between Newly Diagnosed and Recurrent Glioblastomas
por: Takei, Jun, et al.
Publicado: (2022)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
por: Oza, Amit M, et al.
Publicado: (2015)

Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial
por: Buchroithner, Johanna, et al.
Publicado: (2018)

A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study
por: Kudulaiti, Nijiati, et al.
Publicado: (2021)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

Subclassification of Newly Diagnosed Glioblastomas through an Immunohistochemical Approach
por: Conroy, Siobhan, et al.
Publicado: (2014)

Radiotherapy for Newly Diagnosed Glioblastoma in the Elderly: What Is the Standard?
por: Wee, Chan Woo
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ruhvatd22o34ocvgj92t7nud08